SCHEMBL476528

SCHEMBL476528

NNc1ncc(C(=O)O)cc1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.47
MAPT P10636 3/20 0.47
HCAR2 Q8TDS4 1/20 0.44
NAPRT Q6XQN6 1/20 0.44
TTR P02766 1/20 0.44
TSHR P16473 1/20 0.42
PLAU P00749 1/20 0.41
KDM4E B2RXH2 4/20 0.40
GABRP O00591 1/20 0.40
GABRD O14764 1/20 0.40
GABRA1 P14867 1/20 0.40
GABRB1 P18505 1/20 0.40
GABRG2 P18507 1/20 0.40
GABRB3 P28472 1/20 0.40
GABRA5 P31644 1/20 0.40
GABRA3 P34903 1/20 0.40
GABRA2 P47869 1/20 0.40
GABRB2 P47870 1/20 0.40
GABRA4 P48169 1/20 0.40
GABRE P78334 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31132753 1.00 ALDH1A1 (0.47) ALDH1A1MAPTHCAR2NAPRTTTR
SCHEMBL218035 0.84 KDM4E (0.49) ALDH1A1MAPTKDM4ELMNAKMT2A
SCHEMBL9648858 0.81 ALDH1A1 (0.43) ALDH1A1HCAR2NAPRTTTRTSHR
SCHEMBL6606946 0.81 ALDH1A1 (0.41) ALDH1A1MAPTHCAR2NAPRTTTR
SCHEMBL23832226 0.80 HCAR2 (0.43) ALDH1A1HCAR2KDM4EGABRPGABRD
SCHEMBL30195836 0.80 HCAR2 (0.43) ALDH1A1HCAR2KDM4EGABRPGABRD
SCHEMBL3635781 0.78 HCAR3 (0.54) MEN1LMNAKMT2ANPC1RAB9A
SCHEMBL2421299 0.78 ALDH1A1 (0.41) ALDH1A1HCAR2NAPRTTTRTSHR
SCHEMBL990334 0.77 GRM5 (0.58) MAPTMEN1KMT2ATDP1POLB
SCHEMBL25933680 0.77 HCAR3 (0.54) ALDH1A1POLBHCAR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2410857-A1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN Merck Sharp & Dohme Corp. (US) 2012-02-01 EP disclosed
CN-1984976-B Aqueous vinyl polymer coating compositions DSM IP ASSETS BV 2011-05-18 CN disclosed
WO-2010111058-A1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK SHARP & DOHME CORP. (US) 2010-09-30 WO disclosed
EP-1458684-B1 THERAPEUTIC HETEROCYCLES AS BRADYKININ B2 RECEPTOR ANTAGONISTS ASTRAZENECA AB (SE) 2008-01-16 EP disclosed
CN-1984976-A Aqueous vinyl polymer coating compositions DSM IP ASSETS BV (NL) 2007-06-20 CN disclosed
US-20050245503-A1 Therapeutic heterocycles ASTRAZENECA AB (SE) 2005-11-03 US disclosed
EP-1458684-A2 THERAPEUTIC HETEROCYCLES AstraZeneca AB (SE) 2004-09-22 EP disclosed
WO-2003051276-A2 THERAPEUTIC HETEROCYCLES ASTRAZENECA AB (SE) 2003-06-26 WO disclosed
EP-0332326-B1 POLYURETHANE COATING COMPOSITIONS ICI RESINS BV (NL) 1993-03-03 EP disclosed
EP-0332326-A2 Polyurethane coating compositions ICI RESINS BV (NL) 1989-09-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245503-A1 Therapeutic heterocycles OPRK1, RECQL, OPRM1 ALDH1A1 2117/4885MAPT 4133/4885HCAR2 445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.